Lasek W - Search Results

1

Synergistic cytotoxic effect of sulindac and pyrrolidine dithiocarbamate against ovarian cancer cells.

Jakubowska-Mućka A, Sieńko J, Zapała Ł, Wolny R, Lasek W. Jakubowska-Mućka A, et al. Among authors: lasek w. Oncol Rep. 2012 Apr;27(4):1245-50. doi: 10.3892/or.2012.1639. Epub 2012 Jan 16. Oncol Rep. 2012. PMID: 22266802 Free PMC article.

2

[Antitumor effects of sulindac in ovarian cell cultures].

Jakubowska-Mućka A, Sieńko J, Switaj T, Gołab J, Lasek W. Jakubowska-Mućka A, et al. Among authors: lasek w. Ginekol Pol. 2011 Mar;82(3):195-9. Ginekol Pol. 2011. PMID: 21735687 Polish.

3

Synergistic antitumor effect of JAWSII dendritic cells and interleukin 12 in a melanoma mouse model.

Zapała Ł, Wolny R, Wachowska M, Jakóbisiak M, Lasek W. Zapała Ł, et al. Among authors: lasek w. Oncol Rep. 2013 Mar;29(3):1208-14. doi: 10.3892/or.2012.2193. Epub 2012 Dec 18. Oncol Rep. 2013. PMID: 23254470

4

Interleukin 15 augments antitumor activity of cytokine gene-modified melanoma cell vaccines in a murine model.

Basak GW, Zapala L, Wysocki PJ, Mackiewicz A, Jakóbisiak M, Lasek W. Basak GW, et al. Among authors: lasek w. Oncol Rep. 2008 May;19(5):1173-9. Oncol Rep. 2008. PMID: 18425373

5

Optimization of activation requirements of immature mouse dendritic JAWSII cells for in vivo application.

Zapala L, Drela N, Bil J, Nowis D, Basak GW, Lasek W. Zapala L, et al. Among authors: lasek w. Oncol Rep. 2011 Mar;25(3):831-40. doi: 10.3892/or.2010.1128. Epub 2010 Dec 28. Oncol Rep. 2011. PMID: 21206981

6

Potentialization of N-a-tosyl-L-phenylalanine chloromethyl ketone (TPCK) cytotoxic activity by 2-(1-adamantylamino)-6-methylpyridine (AdAMP) in human ovarian cancer cells.

Sieńko J, Lasek W, Teliga-Czajkowska J, Smolarczyk R, Czajkowski K. Sieńko J, et al. Among authors: lasek w. Ginekol Pol. 2017;88(6):307-311. doi: 10.5603/GP.a2017.0064. Ginekol Pol. 2017. PMID: 28727129 Free article.

7

Synergistic antitumor effects of histone deacetylase inhibitor scriptaid and bortezomib against ovarian cancer cells.

Janyst K, Janyst M, Siernicka M, Lasek W. Janyst K, et al. Among authors: lasek w. Oncol Rep. 2018 Apr;39(4):1999-2005. doi: 10.3892/or.2018.6248. Epub 2018 Feb 6. Oncol Rep. 2018. PMID: 29436692

8

Therapeutic metastatic prostate cancer vaccines: lessons learnt from urologic oncology.

Lasek W, Zapała Ł. Lasek W, et al. Cent European J Urol. 2021;74(3):300-307. doi: 10.5173/ceju.2021.0094. Epub 2021 Jun 11. Cent European J Urol. 2021. PMID: 34729217 Free PMC article. Review.

9

Stimulation of TNF-alpha production by 2-(1-adamantylamino)-6-methylpyridine (AdAMP) - a novel immunomodulator with potential application in tumour immunotherapy.

Lasek W, Switaj T, Sieńko J, Kasprzycka M, Basak G, Mikłaszewicz P, Maj M, Nowis D, Grzela T, Gołab J, Młynarczuk I, Jalili A, Kamińska B, Dziembowska M, Czajkowski K, Nowaczyk M, Górska A, Kazimierczuk Z. Lasek W, et al. Cancer Chemother Pharmacol. 2002 Sep;50(3):213-22. doi: 10.1007/s00280-002-0496-5. Epub 2002 Jul 31. Cancer Chemother Pharmacol. 2002. PMID: 12203103

10

Augmentation of antitumor efficacy by the combination of actinomycin D with tumor necrosis factor-alpha and interferon-gamma on a melanoma model in mice.

Lasek W, Wańkowicz A, Kuc K, Feleszko W, Giermasz A, Jakóbisiak M. Lasek W, et al. Oncology. 1996 Jan-Feb;53(1):31-7. doi: 10.1159/000227531. Oncology. 1996. PMID: 8570128

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

119 results

Search Page